PLoS BIOLOGY Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 Morris E. Feldman1, Beth Apsel1, Aino Uotila2, Robbie Loewith2, Zachary A. Knight1¤, Davide Ruggero3,

First Page		Document Content
Date: 2011-06-08 05:03:15 Signal transduction Mammalian target of rapamycin Immunosuppressants Macrolides AKT Phosphoinositide 3-kinase Sirolimus GSK-3 Phosphorylation Biology Biochemistry Protein kinases		PLoS BIOLOGY Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 Morris E. Feldman1, Beth Apsel1, Aino Uotila2, Robbie Loewith2, Zachary A. Knight1¤, Davide Ruggero3, Add to Reading List Source URL: www.molbio.unige.ch Download Document from Source Website File Size: 713,51 KB Share Document on Facebook

	BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi DocID: 1rrNB - View Document
	Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2 DocID: 1rmwo - View Document
	EAP Reimbursement Criteria for Frequently Requested Drugs DocID: 1rhhE - View Document
	UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol DocID: 1rakB - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qY7G - View Document